MaxCyte, Inc. (NASDAQ:MXCT) Stake Boosted by Barclays PLC

Barclays PLC boosted its stake in shares of MaxCyte, Inc. (NASDAQ:MXCT) by 329.3% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 165,765 shares of the company’s stock after buying an additional 127,156 shares during the period. Barclays PLC owned about 0.16% of MaxCyte worth $645,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MXCT. Verition Fund Management LLC raised its holdings in shares of MaxCyte by 39.5% during the third quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock valued at $83,000 after acquiring an additional 6,045 shares during the period. Creative Planning raised its stake in MaxCyte by 33.6% during the 3rd quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after purchasing an additional 7,212 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in MaxCyte by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock valued at $79,000 after purchasing an additional 7,930 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in shares of MaxCyte by 25.0% in the second quarter. The Manufacturers Life Insurance Company now owns 42,289 shares of the company’s stock valued at $166,000 after purchasing an additional 8,454 shares in the last quarter. Finally, Chevy Chase Trust Holdings LLC boosted its position in shares of MaxCyte by 0.7% in the third quarter. Chevy Chase Trust Holdings LLC now owns 1,332,048 shares of the company’s stock worth $5,182,000 after buying an additional 9,488 shares during the period. 68.81% of the stock is owned by hedge funds and other institutional investors.

MaxCyte Trading Down 1.5 %

Shares of MaxCyte stock opened at $4.75 on Friday. MaxCyte, Inc. has a 1 year low of $3.16 and a 1 year high of $5.32. The company has a market cap of $502.12 million, a P/E ratio of -13.97 and a beta of 1.29. The stock has a 50-day moving average price of $3.96 and a 200 day moving average price of $4.03.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. The business had revenue of $8.16 million during the quarter, compared to analyst estimates of $7.50 million. During the same period in the prior year, the firm earned ($0.11) earnings per share. On average, equities analysts forecast that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.